Alumis (NASDAQ:ALMS) Trading Down 11.5% on Analyst Downgrade

Shares of Alumis Inc. (NASDAQ:ALMS) fell 11.5% during mid-day trading on Monday after HC Wainwright lowered their price target on the stock from $40.00 to $25.00. HC Wainwright currently has a buy rating on the stock. Alumis traded as low as $22.13 and last traded at $21.9510. 1,630,604 shares were traded during trading, a decline of 47% from the average session volume of 3,057,718 shares. The stock had previously closed at $24.80.

ALMS has been the topic of several other research reports. Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alumis in a research report on Monday, December 29th. Leerink Partners increased their price objective on shares of Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, January 6th. Citigroup restated an “outperform” rating on shares of Alumis in a report on Tuesday, January 6th. Finally, Raymond James Financial initiated coverage on shares of Alumis in a research report on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Alumis presently has a consensus rating of “Moderate Buy” and an average target price of $38.60.

Insider Activity

In other news, major shareholder Foresite Capital Management Vi bought 411,764 shares of the stock in a transaction on Thursday, January 8th. The stock was purchased at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the purchase, the insider owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. The trade was a 7.78% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Foresite Labs, Llc purchased 411,764 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was acquired at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the insider directly owned 5,702,536 shares in the company, valued at $96,943,112. The trade was a 7.78% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 1,823,527 shares of company stock worth $30,999,959. 40.70% of the stock is currently owned by corporate insiders.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target to $55 and kept an “outperform” rating, signaling strong upside from current levels and giving investors a bullish institutional vote of confidence. Oppenheimer raises PT to $55 (Benzinga)
• Positive Sentiment: Morgan Stanley (coverage noted on TipRanks) maintained a Buy rating with a $38 target, citing strong Phase 3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a near‑term clinical/regulatory catalyst. Morgan Stanley maintains Buy (TipRanks)
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating with a $38 target, reinforcing analyst conviction around the clinical story and longer‑term upside. Chardan reaffirms Buy (Benzinga)
• Neutral Sentiment: HC Wainwright trimmed its target from $40 to $25 but left a “buy” rating intact — a mixed signal (reduced upside but continued positive view). HC Wainwright lowers PT to $25 (Benzinga)
• Negative Sentiment: Intraday selling is being attributed to investors locking in gains after roughly a 239% annual rise; technical commentary notes the stock tested/broke short‑term support levels, amplifying the drop. Why Is Alumis Stock Falling Monday? (Benzinga)
• Negative Sentiment: Fundamental pressures remain — recent quarter missed revenue and EPS expectations and the company shows deeply negative margins and ROE — which can make pullbacks sharper and raise the bar for sustained rallies. (Background: Q1 results and metrics)

Hedge Funds Weigh In On Alumis

Several institutional investors have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC purchased a new stake in Alumis in the 2nd quarter valued at about $1,049,000. Trium Capital LLP lifted its holdings in shares of Alumis by 17.9% during the 3rd quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock worth $12,457,000 after acquiring an additional 474,072 shares during the period. General Atlantic L.P. acquired a new stake in shares of Alumis in the second quarter worth approximately $3,893,000. Velan Capital Investment Management LP acquired a new stake in shares of Alumis in the second quarter worth approximately $4,863,000. Finally, AXQ Capital LP purchased a new stake in Alumis in the third quarter valued at approximately $78,000.

Alumis Stock Down 18.5%

The business’s fifty day moving average is $26.50 and its 200-day moving average is $14.67. The stock has a market capitalization of $2.57 billion, a PE ratio of -6.60 and a beta of -2.16.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The company had revenue of $1.93 million for the quarter, compared to analysts’ expectations of $2.75 million. Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%. As a group, sell-side analysts anticipate that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.